ALPEK B de C : receives SBTi approval for its emissions reduction target
July 07, 2022 at 04:24 pm
Share
Reaffirming its commitment to combat climate change
Monterrey, N.L., Mexico. July 7, 2022 - Alpek, S.A.B. de C.V. ("Alpek" or "the Company") announced today that its near-term science-based target has been approved by the Science Based Targets initiative1 (SBTi). The SBTi has validated that the corporate greenhouse gas (GHG) emissions reduction target submitted by Alpek is in conformance with the SBTi Criteria and Recommendations (version 4.2).
The SBTi's Target Validation Team has classified the Company's scope 1 and 2 target ambition and has determined that it is in line with limiting warming to well-below 2°C trajectory which guarantees the Company's efforts to combat climate change. As part of the near-term science-based target, Alpek commits to reduce absolute scope 1 and 2 GHG emissions by 27.5% by 2030 from a 2019 base year. Alpek also commits to reduce scope 3 emissions by 13.5% within the same time frame.
"We are pleased to have received this approval from the SBTi as this reaffirms that Alpek's emissions reduction target is feasible and well-aligned with the Paris Agreement," stated José de Jesús Valdez, Alpek's CEO. "We are confident that by transitioning to fully renewable sources of electricity, improving our energy usage, and generating emission-free steam, among other initiatives, Alpek will be well on its way to meet its targets and continue its path towards carbon neutrality by 2050."
Alpek receives SBTi approval for its emissions reduction target
Reaffirming its commitment to combat climate change
Monterrey, N.L., Mexico. July 7, 2022 - Alpek, S.A.B. de C.V. ("Alpek" or "the Company") announced today that its near-term science-based target has been approved by the Science Based Targets initiative1 (SBTi). The SBTi has validated that the corporate greenhouse gas (GHG) emissions reduction target submitted by Alpek is in conformance with the SBTi Criteria and Recommendations (version 4.2).
The SBTi's Target Validation Team has classified the Company's scope 1 and 2 target ambition and has determined that it is in line with limiting warming to well-below 2°C trajectory which guarantees the Company's efforts to combat climate change. As part of the near-term science-based target, Alpek commits to reduce absolute scope 1 and 2 GHG emissions by 27.5% by 2030 from a 2019 base year. Alpek also commits to reduce scope 3 emissions by 13.5% within the same time frame.
"We are pleased to have received this approval from the SBTi as this reaffirms that Alpek's emissions reduction target is feasible and well-aligned with the Paris Agreement," stated José de Jesús Valdez, Alpek's CEO. "We are confident that by transitioning to fully renewable sources of electricity, improving our energy usage, and generating emission-free steam, among other initiatives, Alpek will be well on its way to meet its targets and continue its path towards carbon neutrality by 2050."
share this post
download as PDF
download as PDF
Attachments
Original Link
Original Document
Permalink
Disclaimer
Alpek SAB de CV published this content on 07 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 July 2022 20:23:12 UTC.
Alpek SAB de CV is a Mexico-based company engaged in the chemicals sector. The Company's activities are divided into two business segments: Polyester and Plastics & Chemicals. The Polyester division focuses on the manufacture and distribution of purified terephthalic acid (PTA), polyethylene terephthalate (PET) and polyester fiber. The Plastics & Chemicals division is responsible for the production of polypropylene (PP), expandable polystyrene (EPS), caprolactam (CPL), ammonium sulfate, as well as specialty and industrial chemicals, such as surfactants, ethoxilates, glycoethers and desemulsionates. The Company's products are used in a range of industries, including consumer goods, food and beverages, automotive, construction, agriculture, oil and gas, as well as pharmaceuticals. It operates a number of production plants in the Americas. The Company is controlled by Alfa SAB de CV.